Radiation After Surgery Lowers Chances of Breast Cancer's
TUESDAY, Dec. 7 (HealthDay News) -- Women with localized breast
cancer are less likely to develop invasive cancer if they receive
radiation after surgery, a new study finds.
The researchers also found that treatment with the drug
tamoxifen greatly reduced the risk of the recurrence of localized
The three-nation study included patients with ductal carcinoma
in situ (DCIS), the most common type of noninvasive breast cancer,
who were followed for a median of 12.7 years.
The researchers found that radiation after surgery reduced the
risk of invasive cancer in the same breast by nearly 70 percent and
decreased recurrent DCIS in the same breast by more than 60
percent. Radiation therapy had no effect on the other breast.
"This study is very important in confirming the benefits of radiotherapy in the treatment of ductal carcinoma in situ and, most importantly, decreasing the incidence of invasive carcinoma developing in the same breast," said Dr. Lauren Cassell, chief of breast surgery at Lenox Hill Hospital in New York City. "If we could only identify which particular patients were most at risk, we could target our radiotherapy to those patients who truly benefit from it and avoid over-treating others."
The study also found that treatment with tamoxifen lowered the
risk of cancer recurrence in the same breast by about 30 percent,
and it decreased the risk of new cancer in the other breast by more
than 65 percent.
The findings appear online Dec. 7 in
The Lancet Oncology.
The findings confirm "the long-term beneficial effect of
radiotherapy and reports a benefit for tamoxifen in reducing local
and contralateral new breast events for women with DCIS treated by
complete excision," study author Jack Cuzick, of Cancer Research
U.K. and Queen Mary's School of Medicine and Dentistry in London,
and colleagues wrote in a news release from the journal.
"This trial emphasizes the importance of radiotherapy in high-grade [more quickly growing and more likely to spread] DCIS and also suggests a role for tamoxifen, primarily for new contralateral disease," they concluded.
The American Cancer Society has more about
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.